The carboxyl-terminal domains of secretin family peptides have been shown to contain key determinants for high affinity binding to their receptors. In this work, we have examined the interaction between carboxyl-terminal residues within secretin and the prototypic secretin receptor. We previously utilized photoaffinity labeling to demonstrate spatial approximation between secretin residue 22 and the receptor domain that includes the first 30 residues of the amino terminus (Dong, Detailed understanding of the molecular basis of ligand binding and receptor activation will be the key to facilitate the rational design of new drugs. Guanine nucleotide-binding protein (G protein)-coupled receptors represent the largest group of plasma membrane receptors and include many potentially important targets for therapeutic agents, making this superfamily an ideal focus for these efforts.
Detailed understanding of the molecular basis of ligand binding and receptor activation will be the key to facilitate the rational design of new drugs. Guanine nucleotide-binding protein (G protein)-coupled receptors represent the largest group of plasma membrane receptors and include many potentially important targets for therapeutic agents, making this superfamily an ideal focus for these efforts.
This superfamily includes receptor families that share sequence homologies and structural similarities of their natural ligands. Among these is the recently described class II family that includes receptors for secretin, calcitonin, parathyroid hormone, glucagon, vasoactive intestinal polypeptide, and pituitary adenylate cyclase-activating polypeptide (3, 4) . The natural agonist ligands of these receptors have helical domains in both carboxyl-terminal and amino-terminal regions (5, 6) and have binding determinants that are spread throughout their entire length (3, 4, 7) . The theme is emerging that aminoterminal regions of these peptides contain key determinants for receptor selectivity, whereas carboxyl-terminal regions contain determinants for high affinity binding (8, 9) . Of note, the carboxyl-terminal regions of some of the members of this family may even be interchanged while maintaining high affinity binding (9) . This feature supports the likely general relevance of the observations in the current work to the entire class II family.
We recently used affinity labeling to demonstrate spatial approximation between a photolabile residue within the carboxyl-terminal half of secretin (position 22) and a 30-residue segment at the distal amino terminus of its prototypic secretin receptor (1) . Of interest, the amino-terminal tail of the class II G protein-coupled receptor family has remarkable structural features and major functional importance (3, 4) . This receptor domain is moderately large, containing greater than 110 residues, with six conserved Cys residues and key disulfide bonds (10) . Chemical reduction and treatment with sulfhydryl-reactive compounds have had substantial negative impact on these receptors (10 -12) . Truncation, site-directed mutagenesis, and chimeric receptor studies have also supported the critical role of this domain in the function of this receptor family (9, 13) .
In the present work, we have extended our understanding of the siting of secretin residue 22 when bound to its receptor by defining a receptor residue adjacent to it. We have also established spatial approximation between another residue closer to the carboxyl terminus of secretin (in position 26 of this 27-residue peptide) and a residue within this receptor. Both of these efforts relied on photolabile ligand probes that bound to the secretin receptor specifically with high affinity and represented full agonists. These efforts were also dependent on a series of receptor site mutants that bound ligand and signaled like wild type receptors but that could be chemically cleaved close to the sites of covalent attachment of the radiolabeled probe for the application of Edman degradation sequencing to identify the labeled residue.
These two new pairs of residue-residue approximation should contribute substantially to our understanding of the natural ligand-binding site of the secretin receptor and will likely have relevance for other members of this family. We postulate the existence of a common platform for natural ligand binding that is present within the amino-terminal tail of these receptors. With our recent insight of approximation between an amino-terminal residue (position 6) of secretin and the same domain of the secretin receptor (2), it is possible that such a platform could provide most of the molecular determinants for natural agonist ligand binding.
EXPERIMENTAL PROCEDURES
Materials-Cyanogen bromide (CNBr) and the solid phase oxidant, N-chloro-benzenesulfonamide (IODO-BEADS), were from Pierce. Wheat germ agglutinin-agarose was from EY Laboratories, Inc. (San Mateo, CA). Endoproteinase Lys-C was from Calbiochem. Anti-HA 1 (hemagglutinin epitope) monoclonal antibodies (12CA5 and 3F10) were from Roche Molecular Biochemicals. [3,4,5- 3 H]L-Leucine (150 Ci/mmol) was from NEN Life Science Products. Endoglycosidase F was prepared in our laboratory (14) . All other reagents were analytical grade.
Peptides probe), were synthesized by manual solid phase techniques and purified to homogeneity by reversed phase high performance liquid chromatography (HPLC) using methods analogous to those that we previously reported (15) . Chemical identities of the synthetic peptides were established by mass spectrometry. They were radioiodinated oxidatively and purified by reversed phase HPLC to specific radioactivities of 2,000 Ci/mmol, using techniques previously reported (15) .
Receptor-bearing Cell Lines-Chinese hamster ovary (CHO) cell lines stably expressing wild type secretin receptor (CHO-SecR), HA-tagged receptor constructs (CHO-SecR-HA37 and CHO-SecR-HA79), and Val 16 to Met (V16M) mutant receptors (CHO-SecR-V16M-HA37) have been established and reported previously (1, 2, 16) . Each of these secretin receptor constructs has been demonstrated to be expressed on the cell surface and to bind with appropriate specificity and high affinity (1, 2, 16) . Development of new secretin receptor mutants that incorporated additional sites for CNBr cleavage in key positions was necessary for the current work. These represented Ala 41 to Met (A41M) and Val 13 to Met (V13M) receptor mutants that were prepared by polymerase chain reaction mutagenesis (17) , with the products verified by direct DNA sequencing (18) . A clonal cell line stably expressing the A41M receptor mutant was established by lipofection of CHO-K1 cells, with sequential G418 selection, fluorescent cell sorting, and limiting dilution, as we previously reported (1). These cell lines were cultured at 37°C in a 5% CO 2 environment on Costar tissue culture plasticware in Ham's F-12 medium supplemented with 5% fetal clone-2 (HyClone Laboratories, Logan, UT). Cells were passaged twice a week and lifted mechanically before use. The V13M mutant receptor construct was expressed transiently on COS-7 cells (American Type Cell Collection, Manassas, VA) after transfection using a modification of the DEAE-dextran method (13) . These cells were harvested mechanically 72 h after transfection.
Biological Activity Studies-The agonist activity of [Tyr 10 ,Bpa 26 ]rat secretin-27 was studied using an assay for stimulation of cAMP in CHO-SecR cells that utilized a competition-binding assay with reagents from Diagnostic Products Corp. (Los Angeles, CA). Cells were stimulated with this secretin analogue for 30 min at 37°C, and the reaction was stopped by adding ice-cold perchloric acid. After adjusting the pH to 6 with KHCO 3 , cell lysates were cleared by centrifugation at 3,000 rpm for 10 min, and supernatants were introduced into the assay as described previously (19) . Radioactivity was quantified by scintillation counting. This assay was also used to functionally characterize the new receptor mutants.
Ligand Binding Studies-Cell membranes were prepared from secretin receptor-bearing cells using methods we previously reported (20) . For binding characterization, membranes (5-10 g) were incubated with a constant amount of radioligand, 125 I-[Tyr 10 ]rat secretin-27 (3-5 pM), in the presence of increasing concentrations of non-radiolabeled secretin analogue (0 -1 M) for 1 h at room temperature in KrebsRingers/HEPES medium (25 mM HEPES, pH 7.4, 104 mM NaCl, 5 mM KCl, 1.2 mM MgSO 4 , 2 mM CaCl 2 , 1 mM KH 2 PO 4 , 0.2% bovine serum albumin, 0.01% soybean trypsin inhibitor, and 1 mM phenylmethylsulfonyl fluoride). Bound and free radioligands were separated using a Skatron cell harvester (Molecular Devices, Sunnyvale, CA) with glass fiber filter mats that had been soaked in 0.3% Polybrene for 1 h, and bound radioactivity was quantified in a gamma-spectrometer. Nonspecific binding was determined in the presence of 1 M secretin and represented less than 20% of total bound radioactivity. ]rat secretin-27 in the absence or presence of increasing concentrations of non-radioactive secretin (0 -1 M) prior to photolysis. This was performed for 30 min at 4°C in a Rayonet photochemical reactor (Southern New England Ultraviolet, Hamden, CT) equipped with 3500-Å lamps. Membranes were solubilized in SDS sample buffer, and proteins were separated on 10% SDS-polyacrylamide gels by electrophoresis under the conditions of Laemmli (21) . Radiolabeled bands were detected by autoradiography.
Affinity Labeling Studies-For
CNBr and endoproteinase Lys-C were used separately and in sequence to cleave the labeled secretin receptor and its fragments following procedures previously described (1) . Affinity labeled secretin receptor was typically resolved on 10% SDS-polyacrylamide gels, and radiolabeled products of digestion were resolved on 10% NuPAGE gels using MES running buffer (Invitrogen, Carlsbad, CA). After electrophoresis, labeled bands were identified by exposure to x-ray film with intensifying screens at Ϫ80°C.
Aliquots of affinity labeled secretin receptor and relevant receptor fragments were deglycosylated by treatment for 18 h at 37°C with 2 units of endoglycosidase F in buffer containing 0.1 M NaH 2 PO 4 , pH 6.1, 50 mM EDTA, 1% Nonidet P-40, 0.1% SDS, 1% (v/v) 2-mecaptoethanol. Products were resolved by electrophoresis, as described above. In some cases, products of endoglycosidase F treatment were acetone-precipitated for further enzymatic cleavage (2) .
Identification of some affinity labeled secretin receptor fragments was achieved using immunoprecipitation of affinity labeled intact and digested HA-tagged receptor constructs using anti-HA monoclonal antibody, as we previously described (1, 2). These receptor constructs have previously been fully validated as binding secretin like wild type secretin receptor (1) . Identifications of the labeled receptor fragments were further confirmed by modifications of electrophoretic migration of bands after additional mutagenesis to incorporate new specific sites of cleavage or by use of multiple independent cleavage methods.
Determination of Site of Covalent Attachment-After achieving definitive identification of the receptor fragment that was labeled with a distinct probe, its site of attachment was determined using radiochemical Edman degradation sequencing, as we previously reported (2, 22) . For this, purified radiolabeled receptor fragments were covalently coupled through their Cys residues to N-(2-aminoethyl-1)-3-aminopropyl glass beads (Sigma) using maleimidobenzoyl succinimide. This was followed by repetitive cycles of manual Edman degradation with quantitation of radioactivity released in each cycle (22) .
Biosynthetic labeling of the secretin receptor was achieved by culturing the cell line expressing the epitope-tagged receptor construct (SecR-HA37) in 90% leucine-free RPMI medium containing 5% Fetal Clone-2 in the presence or absence of 0.5 mCi of [3,4,5- 3 H]L-leucine (150 Ci/mmol) for 8 h, followed by an additional 15 h in complete medium. Membranes were prepared from the cells, as described above. The non-radioactive membranes were photoaffinity labeled with [ 125 ITyr 10 ,Bpa 26 ]secretin-27, as described above. The radioactive biosynthetically labeled membranes were photoaffinity labeled in an analogous manner using non-radioactive [Tyr 10 ,Bpa 26 ]secretin-27. The relevant segment of the secretin receptor from each set of membranes was purified by SDS-polyacrylamide gel electrophoresis, deglycosylation with endoglycosidase F, cleavage with endoproteinase Lys-C, and immunoaffinity purification using anti-HA affinity matrix (3F10). Excess HA peptide (1 mg/ml) was used to elute the immunoadsorbed peptides that were then attached to glass beads through Cys residues and were sequenced by manual Edman degradation, as described above. The radioactivity eluted in each cycle was quantified by counting the relevant reaction in a gamma-spectrometer for 125 I or in a liquid scintillation counter for 3 H. Statistical Analysis-Observations were repeated at least three times in independent experiments and are expressed as the means Ϯ S.E. Binding curves were analyzed and plotted using the nonlinear regression analysis in Prism software (GraphPad Software, San Diego, CA). Binding kinetics were determined by analysis with the LIGAND program of Munson and Rodbard (23) .
RESULTS

Bpa
26 Probe Characterization-The Bpa 26 analogue of secretin contains a Tyr residue at position 10 for radioiodination and a photolabile Bpa residue at position 26 for covalent labeling of its receptor. This analogue was synthesized by manual solid phase techniques, purified by reversed phase HPLC, and had its identity established by mass spectrometry. It was shown to represent a full agonist acting at the secretin receptor (Fig. 1) . It stimulated a concentration-dependent increase in intracellular cAMP accumulation in secretin receptor-bearing CHOSecR cells (cAMP: basal, 3.2 Ϯ 0.6 pmol/million cells; maximal, 190 Ϯ 17 pmol/million cells). The potency (EC 50 ϭ 72 Ϯ 6 pM) and efficacy of this peptide analogue were similar to these characteristics of natural secretin (EC 50 ϭ 47 Ϯ 7 pM). This analogue also bound to the secretin receptor on these cells saturably (B max ϭ 100 pmol/mg protein) and with high affinity (K i ϭ 10.3 Ϯ 2.4 nM), similar to natural secretin (K i ϭ 4.9 Ϯ 0.9 nM). As expected for a secretin receptor, vasoactive intestinal polypeptide had lower affinity and was less effective in competing for this binding (IC 50 Ͼ1 M).
Photoaffinity Labeling of the Secretin Receptor with the Bpa 26 Probe-The Bpa 26 analogue covalently labeled the secretin receptor saturably, specifically, and with high affinity (IC 50 ϭ 4.1 Ϯ 1.8 nM) (Fig. 2) . Consistent with our previous work, the labeled receptor band migrated at M r ϭ 70,000 and shifted to M r ϭ 42,000 after deglycosylation with endoglycosidase F (2). This band was not present in samples prepared from nonreceptor-bearing parental CHO-K1 cell membranes. The labeled band from CHO-SecR cells has been purified to homogeneity and partially sequenced to document its identity as the secretin receptor (data not shown). 26 ProbeCNBr cleavage was used to gain initial insight into the domain of labeling the secretin receptor (Fig. 3) . Digestion of the intact receptor yielded a labeled M r ϭ 19,000 band that shifted to M r ϭ 10,000 after deglycosylation. This pattern of migration is identical to that we reported for labeling this receptor with both the Bpa 22 and Bpa 6 probes (1, 2). Considering the mass of the Bpa 26 probe (3, 341 Da) and this evidence of glycosylation of the labeled peptide, the first and third CNBr fragments of the secretin receptor are the best candidates to fit these data. We have previously established the sites of glycosylation of the secretin receptor that are utilized (24) .
Identification of the Site of Labeling by the Bpa
We definitively identified the domain of this receptor that was labeled by using specific immunoprecipitation of fragments of two distinct secretin receptor constructs incorporating HA epitope tags that were incorporated within each of the candidate domains. These receptor constructs have previously been fully characterized to establish their expression on the cell surface and their binding and signaling like wild type secretin receptor (1). Fig. 4 demonstrates that both of these constructs were affinity labeled with this probe and that both intact receptors were recognized by this antibody. However, after CNBr cleavage only the immunoprecipitated fragment from the HA37 construct (epitope tag within fragment one) was radioactive.
The site of secretin receptor labeling was further localized by cleavage with endoproteinase Lys-C. This protease would theoretically separate CNBr fragment one into an amino-terminal non-glycosylated 3,425-dalton fragment, a glycosylated fragment with 1,808-dalton core, and two tiny fragments inbetween (Fig. 5) . Lys-C cleavage of CNBr fragment one yielded a labeled M r ϭ 14,000 band that shifted to M r ϭ 6,000 after deglycosylation, consistent with representing the glycosylated region between Gly 34 and Met 51 . A buffer incubation control did not shift the migration of the labeled CNBr fragment (data not shown). Also consistent with this identification was the larger labeled band (M r ϭ 8,000, representing the region between Gly 34 and Lys 69 ) observed after Lys-C cleavage of the deglycosylated intact receptor (eliminating the CNBr cleavage at Met 51 ). Further localization of the site of labeling was achieved using a cell line expressing a receptor mutant with Ala 41 changed to Met (A41M) to introduce an additional site for CNBr cleavage. This construct was characterized to demonstrate its normal binding (K i ϭ 7.0 Ϯ 0.5 nM) and cAMP responses to secretin (EC 50 ϭ 200 Ϯ 30 pM) (Fig. 6) . It was also specifically and saturably affinity labeled with the Bpa 26 probe, with the labeled band migrating at M r ϭ 70,000 and shifting to M r ϭ 42,000 after deglycosylation (Fig. 7) . Cleavage with CNBr yielded a fragment migrating at M r ϭ 7,500 that did not shift after deglycosylation, thus representing the first 41 residues of the secretin receptor. Combined with the previous data, this allowed the further localization of the site of covalent attachment of this probe to the region between Gly 34 and Ala 41 . Identification of the specific residue that was labeled with the Bpa 26 probe was achieved by manual Edman degradation sequencing of the purified deglycosylated Lys-C fragment of the wild type receptor (Fig. 8) . In three independent experiments, the peak in eluted radioactivity appeared consistently in cycle 3, corresponding to the covalent labeling of receptor residue Leu 36 . Identical results were observed when sequencing the labeled fragment purified after CNBr cleavage and subsequent Lys-C cleavage (data not shown).
Further confirmation of the identity of the covalently labeled residue as Leu 36 came from biosynthetic labeling studies. In these, [ 3 H]Leu was incorporated into newly synthesized proteins in the SecR-HA37-expressing CHO cell line. In parallel, non-radioactive Leu was similarly incorporated under analogous conditions. For ]secretin-27 was used. Both preparations were then solubilized, and the receptor was resolved on an SDSpolyacrylamide gel, deglycosylated with endoglycosidase F, and cleaved with endoproteinase Lys-C, and the relevant fragment was purified by immunoaffinity chromatography. The specifically bound fragments were eluted with excess HA peptide, bound to glass beads via their Cys residues, and carried through cycles of Edman degradation sequencing. Eluted radioactivity was quantified in each cycle (Fig. 9) . Consistent with the cycle sequencing of the Lys-C fragment of the photoaffinity labeled wild type receptor, the radioiodinated ligand was covalently attached to the residue eluting in cycle 3 of the epitope-tagged receptor construct. This was the same position of the eluted [ 3 H]Leu that had been biosynthetically incorporated into this protein. 26 Probe-A cell line expressing the V16M-HA37 construct that had been characterized previously (2) was used to help localize the site of receptor labeling with the Bpa 22 probe. In addition, cells were prepared that expressed the V13M-HA37 secretin receptor mutant. This receptor construct also bound secretin with normal affinity (K i ϭ 10.8 Ϯ 1.3 nM) and exhibited cAMP responsiveness to secretin, with this stimulated in a concentration-dependent manner (EC 50 ϭ 900 Ϯ 100 pM) (Fig. 6) .
The Bpa 22 probe affinity-labeled the V16M-HA37 and V13M-HA37 receptor constructs in a specific and saturable manner FIG. 2 . Photoaffinity labeling of the secretin receptor. The Bpa 26 probe labeled the secretin receptor in a specific and saturable manner. The representative autoradiograph shows the labeled receptor migrating at M r ϭ 70,000 and shifting to M r ϭ 42,000 after deglycosylation with endoglycosidase F (EF). This band was absent after labeling non-receptor-bearing CHO cell membranes. Shown also is the densitometric analysis of four similar experiments (means Ϯ S.E.).
FIG. 3.
CNBr cleavage of the affinity labeled receptor. CNBr cleavage of the secretin receptor results in fragments ranging in mass from 1 to 11 kDa, three of which contain sites of glycosylation (24) . Shown is a representative autoradiograph of a 10% NuPAGE gel used to separate the products of CNBr cleavage of the secretin receptor labeled with the Bpa 26 probe. The labeled fragment migrated at M r ϭ 19,000 and shifted to M r ϭ 10,000 after deglycosylation with endoglycosidase F (EF). The best potential candidates to represent this domain of labeling are the first and third fragments at the amino terminus of this receptor.
FIG. 4. Identification of the domain of labeling by immunoprecipitation.
Two well characterized HA37-and HA79-tagged secretin receptor constructs (sequences of epitope tags noted as loops) (1) were used in immunoprecipitation experiments. The left lanes show that both constructs were affinity labeled with the Bpa 26 probe and were specifically recognized by anti-HA monoclonal antibody (ϩ and Ϫ designates the presence or absence of competing HA peptide in the immunoprecipitation), whereas the right control lanes show that both constructs were fully cleaved prior to their attempted precipitation. The key middle lanes show that only the immunoprecipitated fragment containing the HA-37 tag was radioactive. This provides definitive identification of CNBr fragment one as the affinity-labeled receptor domain. (Fig. 10) . The labeled mutant receptors migrated at approximate M r ϭ 70,000, shifting to M r ϭ 42,000 after deglycosylation. CNBr cleavage of these constructs yielded labeled fragments migrating at approximate M r ϭ 19,000 that shifted to M r ϭ 9,000 after deglycosylation, most consistent with the region containing the site of glycosylation extending from Leu 17 to Met 51 (Fig. 10) . Considering our previous demonstration of labeling within the first 30 residues (Ala 1 to Lys 30 ) (1), this localizes the site of covalent labeling with the Bpa 22 probe to the region between Leu 17 and Lys 30 . Identification of the specific residue that was labeled with the Bpa 22 probe was achieved by manual Edman degradation of the purified CNBr fragments of V16M-HA37 and V13M-HA37 receptor mutants. Peaks in eluted radioactivity appeared consistently in cycle 1 for the CNBr fragment of the V16M-HA37 construct and in cycle 4 for the fragment from the V13M-HA37 construct. Both peaks correspond with covalent attachment of the Bpa 22 probe to Leu 17 of the secretin receptor (Fig. 11) .
DISCUSSION
The rational design of new receptor-active drugs can be greatly facilitated by detailed molecular insights into the active conformation of a receptor and into the molecular basis of its binding of agonist ligands. Unfortunately, our understanding of the conformation of receptors in the class II family of G protein-coupled receptors is quite limited, being largely confined to the theoretical prediction of the confluence of helices (25, 26) . These predictions have been based on existing helical bundle models of class I G protein-coupled receptors (27) (28) (29) , with refinement based on sequence homologies between class I and II receptors, as well as the chemical character of residues that are conserved and divergent among the members of the class II family. The amino-terminal tail and extracellular loop regions that have been shown to be relevant to natural ligand binding for these receptors have been absent from such models. In contrast, we have made substantial progress toward the elucidation of the molecular basis of the binding of a natural agonist ligand to the prototypic secretin receptor by identifying specific residues in these molecules that are spatially approximated. As we expand the number of such contacts that are experimentally derived, our insights into this important long term effort will grow.
The natural ligands for the class II receptor family are relatively large peptides that have diffuse pharmacophoric domains extending throughout the entire molecule. In this work, we have focused on the molecular basis of docking the carboxylterminal domain of secretin. This is a domain with conserved structural features among members of the family that has been shown to be critical for high affinity binding (8, 9) . This region can even be interchanged among some family members without negative impact on action (9) . In contrast, the amino-terminal domain of these peptides is typically quite important for agonist selectivity (9) .
We recently demonstrated that a secretin ligand with a photolabile Bpa residue within the carboxyl-terminal half of the ligand, at position 22, labeled a segment representing the first 30 amino acids of the secretin receptor (1) . In the present work, we have extended this insight by refining this interaction to a specific receptor residue, Leu 17 . We have also developed another novel secretin probe that incorporated a photolabile Bpa residue near the carboxyl terminus of the ligand, in position 26. This probe was a full agonist that bound to its receptor with high affinity. Like the Bpa 22 probe, this probe labeled a residue within the amino-terminal tail of the receptor, in position Leu 36 . The two pairs of approximations between residues within secretin and within its receptor that have been experimentally derived in this effort are extremely important. They can ultimately provide initial alignments for molecular models of docked molecules that can be subsequently manipulated, experimentally tested, and refined. At the present time, we have FIG. 5 . Refinement of the domain of labeling. Lys-C cleavage of affinity-labeled CNBr fragment one yielded a band migrating at M r ϭ 14,000 that shifted to M r ϭ 6,000 after deglycosylation with endoglycosidase F (EF). This is most consistent with representing the glycosylated fragment between Gly 34 and Met
51
. This was further supported by Lys-C cleavage of the deglycosylated non-CNBr-cleaved receptor that yielded a band migrating at M r ϭ 8,000, representing the region between Gly 34 no direct insights into the conformation of the amino-terminal tail domain of this receptor and no adequate experimentally derived constraints for this region to build into a meaningful molecular model. Our insights into the relevant conformation of the secretin peptide to use in such a model are similarly limited. There are no data documenting secondary or tertiary structure of this peptide in aqueous solution, although aminoterminal and carboxyl-terminal helical domains have been observed in certain structure-inducing environments, such as trifluoroethanol or dimethyl sulfoxide (30, 31) . These studies have been predominantly limited to backbone conformation and provide little insight into positions of the functional groups. It is quite interesting that each of the currently established interactions for residues within the carboxyl-terminal domain of secretin involve residues within a limited region of the receptor amino-terminal tail domain. This likely suggests that these functional groups extend from a single face of the ligand. As the number of residue-residue interactions expands, it should be possible to begin to propose a working model based only on these spatial approximations.
The amino-terminal tail domain of the class II G proteincoupled receptors is of great interest. It contains six highly conserved Cys residues and is believed to contribute to key disulfide bonds important for the structure and function of these receptors (3, 4) . Theoretical predictions of conformation have suggested the possibility that a coiled-coil interaction might exist between extended ␣-helices in ligands and in the distal amino-terminal tail domain of receptors in this family (32) . The critical importance of this region has also been experimentally supported by receptor truncation, site-directed mutagenesis, and chimeric receptor studies (9, (33) (34) (35) (36) (37) (38) . Affinity labeling studies have provided direct experimental data to support this interpretation. Such studies have shown that receptor domains at the distal end of the amino terminus and adjacent to the first transmembrane segment are of particular interest (1, 2, 39, 40) . It is possible that both of these two amino-terminal domains reside adjacent to each other in threedimensional space, although no such conformation has been proposed or established. This may become clearer once the disulfide bonds within this domain are mapped to provide further structural constraints.
The most extensive data for docking a natural peptide ligand in this family to its receptor comes from the photoaffinity labeling with analogues of parathyroid hormone. There also, a carboxyl-terminal domain residue (Bpa 23 ) was found to be approximated with parathyroid hormone-1 receptor amino-termi- nal tail residues (Thr 33 and Gln 37 ) (40) . Even a residue in the mid-region of parathyroid hormone (position 13) was found to label a residue within the amino-terminal tail of the receptor, adjacent to the first transmembrane segment (Arg 186 ) (38, 39) . Of great interest, photoaffinity labeling using a probe with a Bpa at the amino terminus of parathyroid hormone, in position 1, labeled Met 425 near the top of the sixth transmembrane segment of the parathyroid hormone-1 receptor (41). Similar results have been obtained with the parathyroid hormone-2 receptor (42). These observations have supported the proposed model for binding of parathyroid hormone to its receptors where the peptide carboxyl terminus interacts with the aminoterminal tail of the receptor, whereas the peptide amino terminus inserts itself into the membrane in the confluence of helices (41, 43, 44) .
Our current data from the labeling of the secretin receptor through carboxyl-terminal residues of secretin (i.e. Bpa 22 and Bpa 26 probes) are consistent with such a model. However, our recent report of photoaffinity labeling of the secretin receptor through an amino-terminal domain residue, Bpa in position 6, may suggest a difference (2) . In that work, the Bpa 6 residue also labeled a receptor residue within the amino-terminal tail domain (Val 4 ). The ultimate test of this hypothesis will be the use of a secretin analogue with a photolabile residue closer to or positioned at its amino terminus, but this has not yet been accomplished. Structure-activity considerations make the design of such a probe challenging (45) .
In summary, we have now identified two additional residueresidue interactions between the carboxyl-terminal domain residues of secretin and its receptor. Thus, we have provided two more spatial constraints that are potentially useful for the molecular modeling of the agonist-occupied secretin receptor. Additional experimentally derived molecular approximations will provide additional constraints for constructing a meaningful and testable molecular model for ligand binding of the secretin receptor that can be ultimately used for other members in the class II family of G protein-coupled receptors. FIG. 10 . Photoaffinity labeling of V13M and V16M secretin receptor constructs with the Bpa 22 probe. Each receptor construct was labeled with the Bpa 22 probe saturably and specifically. The representative autoradiograph shows the labeled receptors migrating at M r ϭ 70,000 and shifting to M r ϭ 42,000 after deglycosylation with endoglycosidase F (EF). CNBr cleavage of each construct yielded bands migrating at approximate M r ϭ 19,000 in its glycosylated form and at approximate M r ϭ 9,000 after deglycosylation (note the slight shift in migration that is appropriate for each of these constructs). This supports the interpretation that the site of labeling for the Bpa 22 probe was within the segment between Leu 17 and the carboxyl terminus of these fragments. WT, wild type.
FIG. 11.
Edman degradation of the fragments labeled with the Bpa 22 probe. Shown are the profiles of eluted radioactivity from the sequencing of CNBr fragments of secretin receptor constructs labeled with the Bpa 22 probe. The peaks in eluted radioactivity were consistently observed in cycle 1 for the V16M-HA37 construct and cycle 4 for the V13M-HA37 construct, corresponding to the covalent attachment of Bpa 22 to Leu 17 of the receptor. a.a., amino acid.
